BigSteve - I agree: lots of unanswered questions. However,
BigSteve - I agree: lots of unanswered questions. However, things havent fel right for a long time.
"Lots of unanswered questions Ragz. I know patience is key here, but some things don't feel right. BTL, the supposed $2 million fees we were getting, SLA's etc. Nothing is being monetized and it's frustrating to watch. How about just an update on shares being bought back, if that's even the case. I would just like some clarification. I, for one, am not buying any more right now, but would with some answers and info. "
Still cant get any answers on the BTL SLA that was "guaranteed " per James/IR in last year CC at $13.5MM for 2017. Also another $1MM SLA that was PRd late in 2016. No word on any EIA revenues nor the ExIM $10MM loan vs $85MM. Now the company is exporting e bikes and bourbon. While I do not care what they import/export through EIA program - to date - NONE of it has brought revenues into the company. Nor did MRVB show revenue in 4Q16 (calendar) and company wont comment on those revenues as well. They only seem to be interested in building up a traders database too move commodity pricing up and down. If it is that lucrative for the company - why not discuss the results in the recent 10Q or provide a separate 8K?
I also dont buy into this driving the price down to buyback shares. For one - that is manipulation and simply illegal. IRMuse already has crossed the lines there not too mention their &D rhetoric on the brief move to 7 when they were encouraging everyone to load over Twitter and then 100MM shares were dumped next day (or day after). Their continued affirmation of year end PPS of $0.01 certainly didnt help credibility. Despite the few posts on here still gung ho - the buy/sell sode doesnt support the rhetoric. If all of this activity was real (SLAs, EIAs, etc) - people would be knocking the doors down tonsecure shares. Instead - we continue to seepattern of large, systematic dumps. Today was another example. There is ZERO confirmation any shares have been bought back and last 10Q shows another 300MM plus in dilution to OS. That is not a buyback.
However, any questions of these obvious disconnects gets one excoriated here and Twitter and stifles any real discussion on the company. Worse - one gets continually flamed over PM on this board and elsewhere. If the news was so good - shouldnt the results speak for themselves? Furthermore-revenues and real, verifiable progress would be the ultimate case against the so called bashers. Stock price is 0.0003. OS is 2.5-3x where it was a year/15 months ago. Still no revenues. No loan. And no confirmation that ANY of the aforementioned SLAs are even valid/producing. Disappointing and frustrating to say the least.
9
Trans-Pacific Aerospace (TPAC) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Permitting news rarely rings a cash register, but it can stop one from being bolted shut. Century Lithium has received confirmation from the Bureau of Land Management’s Tonopah Field Office that baseline studies for its wholly owned Angel Island lithium project in Esmeralda County, Nevada, are complete. The agency also set the project on the Environmental Impact...
Continue Reading
A guidance bump that barely clears the curb can still wreck a stock. That is the unpleasant read-through from Global-E Online's third-quarter 2026 report: revenue guidance went higher, but not high enough to persuade investors that the business was pulling away from expectations. Shares fell after the release, and a securities-law investigation announced November 19 has...
Continue Reading
Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...
Continue Reading
A shuttered Oregon copper-gold deposit just became part of Blue Moon’s puzzle, and the real question is whether the pieces can ever be made to fit cheaply enough to matter. Turner Adds a Nearby VMS Angle Blue Moon Metals has completed its acquisition of the Turner copper-gold deposit in O’Brien, Oregon, from Gold Coast Mining. The formal closing follows the September...
Continue Reading
A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...
Continue Reading
A grocery cart built in thirty seconds can still nick your wallet all week. That is the part buried beneath the convenience pitch around DoorDash's grocery tools: planning is useful, but convenience only earns its keep when the final basket, delivery charge, substitutions, and timing actually line up. The 2026 review from Expert Consumers highlights features that are...
Continue Reading
A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...
Continue Reading
A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...
Continue Reading
Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...
Continue Reading
A bass drop at 11,000 feet is not merely a party trick when you run 42 mountain resorts. Vail Resorts is putting live music, après programming and destination events squarely beside skiing and riding for winter 2026-27, and the business logic is pretty plain: give people another reason to buy early, stay longer and return with friends. For investors watching MTN, this is...
Continue Reading
Top 5 Most Recently Viewed Articles
Siebert Financial Initiates Strategic Funding Initiative Siebert Financial Corp. (NASDAQ: SIEB) has taken a significant step by announcing the effective declaration of its shelf registration statement on Form S-3 by the SEC. This move permits the company to raise an impressive $100 million through a variety of securities offerings. Enhancing Financial Flexibility and...
Continue Reading
BTQ Technologies Introduces Léonne Framework BTQ Technologies Corp. is making waves in the blockchain industry with the unveiling of Léonne, a groundbreaking consensus framework that integrates trust modeling, network analysis, and quantum-resistant cryptography into a cohesive and modular system. This innovative approach positions Léonne as the first of its kind,...
Continue Reading
Matthew Peterson, Ph.D., Joins Annovis Bio as Senior Clinical Scientist Annovis Bio Inc. (NYSE: ANVS) is making headlines with the recent addition of Dr. Matthew Peterson as Senior Clinical Scientist. This strategic appointment comes at a critical juncture for the company, which is dedicated to developing innovative therapies targeting neurodegenerative disorders...
Continue Reading
Ironwood Pharmaceuticals Outlines Strategic Focus on Apraglutide Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading biotechnology company committed to developing innovative therapies for gastrointestinal and rare diseases, has announced a profound strategic shift towards advancing apraglutide, specifically aimed at treating patients with short bowel syndrome (SBS)...
Continue Reading
Chamberlain Group Unveils the Next Generation of Home Security In a groundbreaking move, Chamberlain Group (CG) has introduced the myQ Secure View 3-in-1 Smart Lock, a device that not only acts as a smart lock but also integrates a doorbell and camera. This innovative product marks a significant shift for the company as it extends its reach from garage door innovations to...
Continue Reading